Authors: Mitsiades, N Mitsiades, CS Poulaki, V Anderson, KC Treon, SP

Citation: N. Mitsiades et al., Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma andother neoplasias, EXPERT OP I, 10(8), 2001, pp. 1521-1530

Authors: Mitsiades, N Poulaki, V Mitsiades, CS Anderson, KC

Citation: N. Mitsiades et al., Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors:new tricks from a (not so) old drug, EXPERT OP I, 10(6), 2001, pp. 1075-1084

Authors: Mitsiades, CS Koutsilieris, M

Citation: Cs. Mitsiades et M. Koutsilieris, Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer, EXPERT OP I, 10(6), 2001, pp. 1099-1115

Authors: Mitsiades, N Poulaki, V Mitsiades, CS Koutras, DA Chrousos, GR

Citation: N. Mitsiades et al., Apoptosis induced FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases, TRENDS ENDO, 12(9), 2001, pp. 384-390

Authors: Mitsiades, CS Treon, SP Mitsiades, N Shima, Y Richardson, P Schlossman, R Hideshima, T Anderson, KC

Citation: Cs. Mitsiades et al., TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications, BLOOD, 98(3), 2001, pp. 795-804